|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The anterior uveitis treatment market will show rapid growth due to the increasing cases of the uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.
There has been an increasing prevalence of uveitis as it is responsible for an estimated 30,000 new cases of legal blindness annually in the United States and accounts for about 10–15% of all cases of total blindness in the country. Uveitis is a sight-threatening inflammatory disease affecting the uveal layer of the eye. Redness of eyes, blurring of the vision, the small size of the pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness. Thus, there are new developments in the applications of products and treatment modalities that are ongoing.
New treatment options for uveitis such as corticosteroids and anti-inflammatory drugs are already gaining traction in the market. In addition, other factors such as the growing geriatric population, rising incidence of the disease, and new product developments are also expected to be some of the driving factors in the growth of the market.
Scope of the Report
As per the scope of the report, anterior uveitis is an eye inflammation that involves the middle layer of the eye. Anterior uveitis is the most common form of uveitis and is the most frequent extra-articular manifestation of ankylosing spondylitis (AS) patients. Untreated anterior uveitis results in loss of vision and permanent eye damage that arises with the development of infections such as glaucoma, retinal edema, or cataract. Anterior uveitis can be treated with eye drops containing anti-inflammatory drugs. Corticosteroids have also shown significant results to cure the condition and to treat anterior uveitis.
|By Treatment Type|
|By Distribution Channel|
Key Market Trends
Corticosteroids Segment is Expected to Dominate the Treatment Type Segment During the Forecast Period
Corticosteroids are found dominating the anterior uveitis treatment market as they are first-line therapies for anterior uveitis and are used in the form of eye drops. They are the most preferred option over biologics however researchers are currently exploring biological therapies for the treatment of anterior uveitis.
Corticosteroids are also used in sustained release treatment, i.e., in ocular implants. It has thus shown significant results to cure the condition and researchers are also exploring biological therapies to treat anterior uveitis. In addition, corticosteroids and anti-inflammatory drugs are found gaining traction in the market.
To understand key trends, Download Sample Report
North America is Anticipated to Dominate the Anterior Uveitis Treatment Market
North America is found dominating the market owing to the rising prevalence of the uveitis disease in the United States. There is also an increasing number of key players in the region that is leading to the high growth of this regional segment. The other factors resulting in the growth of the market is the growing geriatric population, and increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids.
In addition, the market in the Asia Pacific is also expanding fast for the same reasons the markets in North America and Europe are expanding.
To understand geography trends, Download Sample Report
There has been a presence of a considerable number of companies that are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. Various companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events.
- In August 2021, Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for difluprednate ophthalmic emulsion 0.05% used for the treatment of endogenous anterior uveitis from the United States Food and Drugs Administration.
- In January 2019, Aldeyra Therapeutics, Inc. had announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of the Uveitis
4.2.2 Development of Novel Drugs and Treatments
4.3 Market Restraints
4.3.1 High Cost Associated with the Medications
4.3.2 Side Effect Associated with Corticosteroid Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment Type
5.1.2 Cycloplegic Agents
5.1.3 Anti-TNF Agents
5.2 By Distribution Channel
5.2.1 Hospitals Pharmacies
5.2.2 Retail Pharmacies
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
5.3.3 Asia Pacific
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Aldeyra Therapeutics, Inc.
6.1.3 Alimera Sciences Inc.,
6.1.4 Clearside Biomedical, Inc.
6.1.5 EyePoint Pharmaceuticals, Inc.
6.1.6 Novartis AG
6.1.7 Regeneron Pharmaceuticals
6.1.8 Bausch & Lomb Incorporated
6.1.9 Sirion Therapeutics, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Anterior Uveitis Treatment Market market is studied from 2018 - 2026.
What is the growth rate of Anterior Uveitis Treatment Market?
The Anterior Uveitis Treatment Market is growing at a CAGR of 5.8% over the next 5 years.
Which region has highest growth rate in Anterior Uveitis Treatment Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Anterior Uveitis Treatment Market?
North America holds highest share in 2020.
Who are the key players in Anterior Uveitis Treatment Market?
Novartis AG, Alimera Sciences Inc.,, AbbVie Inc., Regeneron Pharmaceuticals, EyePoint Pharmaceuticals, Inc. are the major companies operating in Anterior Uveitis Treatment Market.